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Abstract
Carvacrol (CAR), a naturally occurring monoterpenic phenol and food additive, has been shown to have antimicrobials,
antitumor, and antidepressant-like activities. A previous study demonstrated that CAR has the ability to protect liver against
ischemia/reperfusioninjuryinrats.Inthisstudy,weinvestigatedtheprotectiveeffectsofCARoncerebralischemia/reperfusion
injury in a middle cerebral artery occlusion mouse model. We found that CAR (50 mg/kg) significantly reduced infarct volume
and improved neurological deficits after 75 min of ischemia and 24 h of reperfusion. This neuroprotection was in a dose-
dependent manner. Post-treatment with CAR still provided protection on infarct volume when it was administered
intraperitoneally at 2 h after reperfusion; however, intracerebroventricular post-treatment reduced infarct volume even when
the mice were treated with CAR at 6 h after reperfusion. These findings indicated that CAR has an extended therapeutic
window, but delivery strategies may affect the protective effects of CAR. Further, we found that CAR significantly decreased
the level of cleaved caspase-3, a marker of apoptosis, suggesting the anti-apoptotic activity of CAR. Finally, our data indicated
thatCARtreatmentincreased the levelof phosphorylated Aktand theneuroprotectionof CARwasreversed bya PI3Kinhibitor
LY-294002, demonstrating the involvement of the PI3K/Akt pathway in the anti-apoptotic mechanisms of CAR. Due to its
safety and wide use in the food industry, CAR is a promising agent to be translated into clinical trials.
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Introduction
Stroke is one of the three leading causes of death and disability
and ischemic stroke accounts for the majority of stroke [1].
Ischemic stroke results from the occlusion of brain blood vessels,
while the middle cerebral artery is mostly involved in ischemic
stroke. Middle cerebral artery occlusion (MCAO) usually causes
substantial decreases in local cerebral blood flow, thus reducing
perfusion pressure and blood oxygen content, and resulting in an
interdependent series of neurotoxic events, including glutamate
excitotoxicity, Ca
2+ overload, oxidative stress, nitric oxide (NO)
production and inflammation [2,3]. These events after cerebral
ischemia injury finally cause neuronal cell death like apoptosis,
necrosis, necroptosis and autophagy [4,5]. In the past several
decades, pathophysiological process of cerebral ischemia injury
was well advanced, however, only intravenous recombinant tissue
plasminogen activator (tPA) therapy has been approved so far by
the United States Food and Drug Administration for acute
ischemic stroke. Searching for neuroprotective agents, which can
antagonize or reduce injurious biochemical and molecular signal
pathways or increase or enhance the protective pathways, are
considered a major promising strategy for the treatment of acute
ischemic stroke. Therapeutic trials of these neuroprotective agents
proved in animal experiments have not yet shown therapeutic
benefits in human [2,6]. Numerous clinical trials failed in past
decades because either these agents showed no protective effects in
patients or their toxicity/side effects cannot be tolerated by
patients. Searching for neuroprotective agents with minimal side
effects from natural sources like herbs or plants probably represent
an ideal strategy to develop safe and effective agents for stroke
treatment.
Carvacrol (CAR), a monoterpenic phenol, is naturally occurring
in various plants belonging to the family Lamiaceae. It is abundant
in the essential oil fraction of oregano and thyme [7]. CAR has
been widely used both as a food or food additive in the food
industry for long time. In recent years, its multiple functions were
well-studied in different fields. More and more data indicated that
CAR has bactericidal activity [8], fungicidal activity [9,10] and
insecticidal activity [11]. Many studies also demonstrated its
therapeutic potential on different diseases. Two studies indicated
its anti-tumor activity in vitro and in vivo [12,13]. In the central
nervous system, CAR was regarded as a potential drug for
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terase (AChE) activity by using phenolic hydroxyl group of CAR
to bind to AChE and leading to a loss of function of AChE
[14,15,16]. In addition, CAR was found to have an antidepres-
sant-like effect in mice by affecting the dopaminergic system [17].
A recent study showed that CAR has the ability to protect liver
against ischemia/reperfusion (I/R) injury in rats [18]. These
results suggest that CAR, a plant-derived essential oil, may play a
role to protect against cerebral I/R injury. Considering CAR’s
neuroprotective potential and safety to human, in our study, we
examined the neuroprotective effect of CAR against cerebral
ischemia/reperfusion injury by using the middle cerebral artery
occlusion (MCAO) model in mice.
Materials and Methods
Animals
Male ICR mice, 23–28 g, were purchased from SLAC
Company (Shanghai, China). All animal procedures were
approved by the University Committee on Animal Care of
Soochow University.
Experimental groups
Animals were randomly divided into four groups (n=6–10,
each): (I) vehicle-treated group (sham); (II) CAR-treated group
(CAR group); (III) vehicle-treated I/R group (I/R group); (IV)
CAR-treated I/R group (I/R+CAR group). In I/R+CAR group,
the animals were divided into several subgroups: pretreatment
group (2 h before ischemia), post-treatment 0 h, 2 h, 4 h, 6 h, and
7 h groups. The animals were administered either intracerebroa-
ventricularly (i.c.v.) 10 mg CAR in 10 ml saline (Peptide Interna-
tional Inc, Japan) in the CAR-treated groups or 10 ml vehicle
(saline) in the vehicle-treated groups or intraperitoneally (i.p.) 5, 25
and 50 mg/kg body weight CAR or saline.
The middle cerebral artery occlusion (MCAO) model
MCAO was induced by using an intraluminal monofilament as
described before [19]. Briefly, the mouse was anesthetized by chloral
hydrate at a dose of 350 mg/kg body weight (i.p.). The right
common carotid artery (CCA), the right external carotid artery
(ECA) and the internal carotid artery (ICA) were exposed through a
ventral midline neck incision. The ECA was ligated with a silk suture
at 2 mm distal from the ECA–CCA branch and then cut distal from
the ligated point. A silk suture was looped around the CCA and
twisted to block blood flow from the CCA. A small incision was
performed on the ECA 1.5 mm distal from the ECA–CCA branch.
A 6-0 nylon monofilament (Ethilon, Ethicon Inc) coated with silicon
resin (Heraeus, Kulzer, Germany) was introduced through the
incision into the right CCA and advanced 9–11 mm distal to the
carotid bifurcation until a faint resistance was felt for temporary
occlusion of themiddlecerebralartery.Reperfusion wasachieved by
withdrawing the suture after MCAO for indicated time (30 min or
75 min)torestoreblood supplytotheMCAterritory.The silksuture
looped around the CCA was removed and the neck incision was
closed. The sham group underwent the same surgical procedure
except that the monofilament was introduced into the external
carotid artery but not advanced. Body temperature was maintained
at 36.5–37.5uC by means of a heating blanket and a lamp
throughout the procedure from the start of the surgery until the
animals recovered from anesthesia.
To monitor occlusion and reperfusion, the local cerebral blood
flow was measured using a laser-doppler blood flowmeter (Periflux
5010, PERIMED, Sweden) positioned at 1 mm posterior and
3 mm lateral to Bregma.
Intracerebroventricular administration
For the injection of CAR or saline into the lateral ventricle
contralateral to the ischemic side, a small burr hole was made in
the parietal region (0.5 mm posterior and 1.0 mm lateral to the
Bregma on the left side). A 28G needle on a syringe was inserted
into the left lateral ventricle (2.5 mm in depth), and 10 ml of CAR
or saline was injected in 10 min.
Neurological deficit scoring evaluation
Neurological deficits were evaluated according to the following
graded scoring system 24 h after the MCAO. The modified
scoring system was based on a 5-point scale system described
previously [20] : 0, no deficit; 1, flexion of the contralateral torso
and forelimb; 2, turning to the ipsilateral side when held by tail; 3,
leaning to affected side; 4, no spontaneous locomotor activity. If no
deficit was observed after MCAO, the animal was removed from
further study.
Detection of infarction volume
After neurological evaluation, all animals were anesthetized and
decapitated, and the brains were removed. The brains with
subarachnoid hemorrhage and/or clot formation in the MCA
were eliminated from the analysis in this study. All brains were
sliced into 1 mm sections. Slices were incubated for 30 min in a
0.2% solution of 2,3,5-triphenyltetrazolium chloride (TTC; Sigma,
St. Louis, Missouri) at 37uC and then fixed in 10% buffered
formaldehyde solution. For analysis, the sections were photo-
graphed by a high-resolution digital camera (Nikon Coolpix
L110). The cross-sectional area of infarction in the right MCA
territory of each brain slice was determined with a computerized
image analysis system (AlphaEase Image Analysis Software V
3.1.2). The total mean infarct area of each section was calculated
as the average of the area on its rostral and the caudal surface. The
hemispheric lesion volume was calculated as described previously
[21].
Western blot analysis
The animals were sacrificed at indicated time. The ischemic
brains were quickly removed and ischemic area brain tissues were
collected. Proteins were extracted from brain tissue and protein
concentrations were then determined. Proteins (30–60 mg) were
loaded on a 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then electrotransferred to
nitrocellulose membrane. Blots were blocked with PBST
(3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM
NaCl, pH 7.4, 0.1% Tween-20) containing 5% nonfat dry milk for
2 h at 4uC, and then incubated with primary antibodies overnight
with shaking at 4uC. After washing, blots were incubated with
HRP-conjugated secondary antibody in blocking solution for
1.5 h, and developed by the ECL chemiluminescence system
(Thermo Company,West Chester, Pennsylvania, USA) and
captured on autoradiographic films (Kodak Company, Rochester,
New York, USA). Films were then digitalized with a camera and
densitometric analysis of the bands was performed with AlphaEase
Image Analysis Software. Primary antibodies were rabbit poly-
clonal anti-phospho-Akt (Ser473), rabbit polyclonal Akt, rabbit
polyclonal cleaved caspase-3 (Cell Signaling Technology Inc.,
Danvers, Massachusetts), and mouse monoclonal anti-beta-tubulin
(Sigma, St. Louis, Missouri).
Statistical analysis
All data are expressed as mean 6 SEM. Differences between
groups were determined with Student t test for infarct volume;
Neuroprotection of Carvacrol on Cerebral Ischemia
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variance (ANOVA) followed by Tukey’s multiple-comparison test
if there was a significant difference between groups. P,0.05 was
considered statistically significant.
Results
CAR pre-treatment reduced infarct volume and improved
neurological deficits
The molecular structure of CAR was shown in Figure 1A (5-
isopropyl-2-methylphenol). To examine the protective effect of
CAR on cerebral ischemia/reperfusion injury, we performed TTC
staining after 24 h of reperfusion and 75 min of MCAO. Effects of
CAR and vehicle on infarct volume after the transient MCAO are
presented in Figure 1B. There was no detectable infarction in sham
group and CAR group, but a large infarct volume was observed in
I/R group (Figure 1B). CAR pre-treated mice in I/R+CAR group
had a total infarct volume of 33.0362.75%, which was significantly
lower than that in I/R group animals (59.4061.3%; P,0.01)
(Figure 1C). CAR markedly reduced infarct volume by approxi-
mately 44.4% compared with I/R group.
Neurological scores were examined after 75 min of MCAO and
24 h of reperfusion. Evaluation showed no significant neurological
deficits in sham group and CAR group mice, while severe
neurological deficits were observed in the I/R group. The mice in
I/R group consistently showed circling movements, severe paw
flections, or less spontaneous movements. CAR treatment (50 mg/
kg body weight i.p.) significantly improved the neurological deficits
and decreased neurological score (P,0.05, Figure 1D). In I/
R+CAR group mice, fewer movement abnormalities in posture and
circling movements were found compared withthe I/R group mice.
Physiological parameters including heart rate, pH, pO2, pCO2,
temperature, and plasma glucose were measured 30 minutes
before and after MCAO. There were no significant differences in
various physiologic parameters in the mice treated with CAR or
vehicle (Table 1).
The protection of CAR on infarct volume was in a dose-
dependent manner
To evaluate the protective efficiency of CAR on cerebral I/R
injury in the mouse MCAO model, we treated the mice with
different doses of CAR (5, 25, and 50 mg/kg body weight, i.p.).
TTC staining after 75 min of ischemia and 24 h of reperfusion
indicated that CAR pre-treatment at 5 mg/kg body weight did not
reduce infarct volume compared with the I/R group (P.0.05,
Figure 2); however, CAR pre-treatment at 25 and 50 mg/kg body
weight demonstrated significant protection on cerebral ischemia/
reperfusion injury (P,0.05, Figure 2), suggesting the does-
dependent protection of CAR on infarct volume in the mouse
MCAO model. In the following experiments, we chose the dose of
50 mg/kg body weight to study the protection of CAR.
CAR post-treatment had protective effects on cerebral I/R
injury
Because interventions for stroke patients are carried out after a
few hours of artery occlusion in the clinical situation, we tested the
Figure 1. CAR pre-treatment reduced infarct volume and improved neurological deficits after MCAO. Mice were administered (i.p.) with
CAR or saline at 2 h before cerebral ischemia. TTC staining and neurological scores were examined after 75 min of ischemia and 24 h of reperfusion.
(A)The molecular structure of CAR is shown. (B) The representative TTC-stained coronal sections in vehicle-treated mice and CAR-treated mice
(50 mg/kg,i.p.) are shown. (C)Statistical analysis of cerebral infarct volume was performed in I/R group and I/R+CAR group; CAR reduced infarct
volume after cerebral I/R injury. (D)Neurological scores were evaluated according to a 5-points scale system. CAR treatment significantly decreased
neurological deficits. Bars represent mean 6 SEM of 6 brains. *, P,0.05 versus vehicle-treated I/R group.
doi:10.1371/journal.pone.0033584.g001
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First, we treated the mice with CAR at the dose of 50 mg/kg body
weight (i.p.) at 0 h, 2 h, and 4 h after reperfusion. Our data
demonstrated that CAR post-treatment reduced the infarct
volume from 57.862.2% in the control group to 35.862.4% at
0 h after reperfusion and to 48.562.6% at 2 h after reperfusion,
indicating that CAR post-treatment still had significant protective
effects on infarct volume at these two time points (P,0.05,
Figure 3A); however, at the time point of 4 h after reperfusion,
CAR post-treatment did not markedly reduce infarct volume
(55.861.9%, P.0.05, Figure 3A). Due to a short therapeutic
window of CAR post-treatment by i.p. administration, we further
examined the therapeutic effects of CAR post-treatment by i.c.v.
administration at different time points after ischemia. Each mouse
was given 10 mg CAR (i.c.v.) at 2 h, 4 h, 6 h, and 7 h after
reperfusion. Surprisingly, CAR post-treatment by i.c.v. still
protected against cerebal I/R injury even when CAR was
administered at 6 h after reperfusion (P,0.05, Figure 3B). Our
findings indicated that CAR post-treatment has protective effects
on infarct volume, but the delivery of CAR should be modified to
improve its therapeutic efficiency.
CAR decreased apoptotic neurons induced by cerebral I/
R injury
The increasing evidences showed different kinds of cell death
including necrosis, necroptosis, apoptosis, and autophagy in
cerebral I/R injury [4]; however, apoptosis and necrosis are still
considered as the dominant causes of cell death after cerebral I/
R injury. Therefore, we examined whether CAR protects
against cerebral I/R injury by blocking the apoptotic neuronal
death. Cleaved caspase-3 is regarded as a marker of apoptosis;
therefore, we determined the cleaved caspase-3 level after
75 min of ischemia and 24 h of reperfusion by Western blot
analysis. We found that I/R injury caused significant increase of
cleaved caspase-3 compared with control group and sham
group (Figure 4A). CAR treatment decreased the level of
cleaved caspase-3 (Figure 4A). Further quantitative analysis
showed that CAR treatment markedly decreased cleaved
caspase-3 level after MCAO compared with I/R group
(P,0.05, Figure 4B), suggesting the anti-apoptotic activity of
CAR after I/R injury.
CAR increased phosphorylated Akt (p-Akt) level after
cerebral I/R injury
Since our data demonstrated that CAR prevents neuronal
apoptosis after cerebral I/R injury, we explored the signaling
pathways that are involved in the neuroprotection of CAR. We
examined PI3K/Akt pathway, a survival pathway after cerebral
ischemia injury, by detecting p-Akt and total Akt (t-Akt) levels
after cerebral I/R injury and CAR treatment. According to our
previous study [22], we examined p-Akt level in ischemic brain
tissues after 30 min of ischemia and 6 h of reperfusion. Our
results indicated that CAR treatment slightly increased p-Akt
level in the normal brain without I/R injury but no significant
difference was observed compared with sham group (P.0.05,
Figure 5A). In the mouse brain tissues with I/R injury, the ratio
of p-Akt to t-Akt was markedly increased compared with sham
group; however, CAR treatment significantly increased p-Akt
level in the ischemic brains compared with I/R group (Figure 5A).
Quantitative analysis confirmed the difference between I/R
group and I/R+CAR group (P,0.05, Figure 5B), suggesting that
PI3K/Akt pathway is involved in the neuroprotection of CAR on
cerebral I/R injury.
Table 1. Physiological parameters of control and CAR-treated mice.
Saline-Treated Mice CAR-Treated Mice
Before Ischemia After Ischemia Before Ischemia After Ischemia
Heart rate, beats/min 538654 585647 593653 567648
pH 7.2860.02 7.2560.06 7.2660.02 7.2360.05
pO2, mm Hg 92.83611.13 90.1668.65 86.7567.42 88.0065.36
pCO2, mmHg 39.8364.90 42.3664.18 45.1763.89 44.6763.13
Temperature, uC 36.960.14 37.060.13 37.060.18 37.060.16
Glucose, mmol/L 5.7060.18 5.8260.25 5.6360.19 5.7860.22
Physiological parameters were measured at 30 minutes before ischemia or after 75 min of ischemia and 30 min of reperfusion. Data are expressed as mean 6 SEM
(n=6).
doi:10.1371/journal.pone.0033584.t001
Figure 2. The protection of CAR on infarct volume was in a
dose-dependent manner. Mice were administered (i.p.) with CAR at
doses of 5, 25, and 50 mg/kg at 2 h before ischemia. Cerebral infarct
volume was determined by TTC staining after 75 min of ischemia and
24 h of reperfusion. Bars represent mean 6 SEM of 6 brains. *, P,0.05
versus vehicle-treated I/R group.
doi:10.1371/journal.pone.0033584.g002
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on cerebral I/R injury
To further investigate whether the PI3K/Akt pathway mediates
the neuroprotection of CAR in cerebral I/R injury, we treated the
mice with a PI3K inhibitor LY-294002 (i.c.v., 5 ml 10 mM LY-
294002 dissolved in 3% DMSO) at 15 min before ischemia.
Western blot analysis showed that the PI3K inhibitor LY-294002
inhibited the increase of p-Akt level induced by CAR treatment
and almost restored p-Akt level to basal level (Figure 6A). TTC
staining was performed after the treatment with LY-294002 to
evaluate its effects on infarct volume. As expected, LY-294002
treatment almost abolished the protection of CAR (Figure 6B).
The quantitative analysis of infarct volumes indicated the
inhibition of the PI3K/Akt pathway was able to reverse the
neuroprotective effect by CAR treatment after MCAO (P,0.05,
Figure 6C), demonstrating that the PI3K/Akt pathway mediates
the neuroprotection of CAR after cerebral I/R injury.
Discussion
In this study, our data demonstrated for the first time that the
food additive CAR has protective effects on cerebral I/R injury in
a MCAO model by decreasing infarct volume and reducing
neuronal apoptosis (Figures 1, 2 and 4). Post-treatment of CAR
still showed significant protection (Figure 3), indicating its potential
for the clinical translation from bench research. In addition, our
Figure 3. CAR post-treatment reduced infarct volume after cerebral I/R injury. CAR was administered (i.p. and i.c.v.) at different reperfusion
times after 75 min of ischemia. TTC staining for cerebral infarct volume was performed after 24 h reperfusion. (A) Mice were administered CAR
(50 mg/kg, i.p.) and saline at 0 h, 2 h, and 4 h after reperfusion. CAR had no protection on infarct volume when it was administered at 4 h after
reperfusion. (B) Mice were administered with 10 mg CAR (i.c.v.) or saline at 2 h, 4 h, 6 h, and 7 h after reperfusion. CAR still had protective effect when
mice treated with CAR after 6 h of reperfusion. Bars represent mean 6 SEM of 6 brains. *, P,0.05 versus vehicle-treated I/R group.
doi:10.1371/journal.pone.0033584.g003
Figure 4. CAR treatment reduced cleaved caspase-3 level after cerebral I/R injury. Mice were treated with CAR (50 mg/kg, i.p.) or saline 2 h
before ischemia. Cleaved caspase-3 level was determined by Western blot after 75 min of ischemia and 24 h of reperfusion. (A)The representative
photographs show the levels of cleaved caspase-3 and beta-tubulin. Beta-tubulin was used as a loading control. (B)The quantitative analysis indicated
that CAR treatment decreased ratio of cleaved caspase-3 to beta-tubulin. Bars represent mean 6 SEM for samples from 4 brains in each group.
*, P,0.05 versus vehicle-treated I/R group.
doi:10.1371/journal.pone.0033584.g004
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protective mechanisms of CAR on cerebral I/R injury (Figures 5
and 6).
CAR is a natural compound extracted from many plants of
Lamiaceae family as in the genera Origanum and Thymus. It was
widely studied in the past years in different research fields. Studies
indicated that CAR has bactericidal [8], fungicidal [9,10], and
insecticidal activity [11] as a food additive. In the medical and
biological fields, CAR demonstrated its anti-cancer activity on
hepatocellular carcinoma in vitro and in vivo [12,13] and its anti-
Figure 5. CAR treatment increased the activation of Akt after MCAO. Mice were treated with CAR (50 mg/kg, i.p.) or saline 2 h before
ischemia. After 30 min of ischemia and 6 h reperfusion, brain tissues were collected and protein levels were determined by Western blot. (A)The
representative photographs show levels of p-Akt, t-Akt, and beta-tubulin. Beta-tubulin was used as a loading control. (B) Quantitative analysis of the
ratio of p-Akt to t-Akt was performed. Bars represent mean 6 SEM for samples from 4 brains in each group. *, P,0.05 versus sham group; #, P,0.05
I/R group versus I/R+CAR group.
doi:10.1371/journal.pone.0033584.g005
Figure 6. A PI3K inhibitor LY-294002 blocked the neuroprotection of CAR on cerebral I/R injury. Mice were treated with CAR (50 mg/kg,
i.p.) or saline 2 h before ischemia and 5 ml LY-294002 (10 mM) was administered (i.c.v.) at 15 min before ischemia. (A) After 30 min of ischemia and
6 h reperfusion, brain tissues were collected and p-Akt and t-Akt levels were determined by Western blot. The photographs show that LY-294002
treatment inhibited the activation of Akt by CAR. (B) After 75 min of ischemia and 24 h of reperfusion, cerebral infarct volume was determined by TTC
staining. The representative TTC-stained coronal sections demonstrate that LY-294002 treatment abolished the protection of CAR on infarct volume.
(C) Statistical analysis of cerebral infarct volume shows that PI3K inhibitor LY-294002 blocked the protective effects of CAR. I/R+CAR+LY: CAR and LY-
294002-treated I/R group. Bars represent mean 6 SEM of 6–9 brains. *, P,0.05 versus vehicle-treated I/R group.
doi:10.1371/journal.pone.0033584.g006
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protective effect on inflammation induced by lipopolysaccharide,
tumor or autoimmune arthritis [23,24,25]. A recent study
indicated that dietary CAR supplementation prevents high fat
diet-induced obesity by modulating gene expressions that lead to
adipogenesis and inflammation [26]. As for I/R injury, Canbek
et al. demonstrated that CAR protected the biochemical changes in
liver caused by ischemia and reperfusion and no hepatotoxicity at
the applied dosage of CAR was found [18]. In our study, our
findings extended the therapeutic spectrum of CAR and showed
that it is a potent protective agent on cerebral I/R injury.
Because the molecular weight of CAR is very small (only
150.2 g/mol) and it has a lipophilic profile, CAR is believed to
easily and rapidly cross the blood–brain barrier [27,28]; but there
was no direct evidence to prove that. In this study, we treated the
mice intracerebraoventricularly after cerebral I/R injury at
different time points. Our data clearly demonstrated the protective
effect of CAR even when CAR was administered at 6 h after
reperfusion (Figure 3B), suggesting there is an extended therapeu-
tic window for CAR in the MCAO mouse model. While this
treatment was administered intraperitoneally, the therapeutic
window was significant shorten that CAR had no protective effect
when CAR treatment was given at 4 h after reperfusion
(Figure 3A). These data suggested that CAR is a high potent
neuroprotector on cerebral I/R injury, drug delivery method like
intraperitoneal may affect its protective efficiency. The improve-
ment of drug delivery of CAR such as using nanoformulation
method will make it easier and higher potent for stroke treatment
because the strategy of nanoformulation into liposomes can
circumvent solubility, stability, and bioavailability problems [24].
The protective mechanisms of CAR on different diseases were
still unclear. Melo et al. found that CAR has anti-depressant-like
and anxiolytic-like effects in mice by using behavioral test and
concluded that the effect of CAR may be mediated by modulating
GABAergic transmission and dopaminergic system [17,29].
Boskabady et al. demonstrated the inhibitory effect of CAR on
muscarinic receptors in guinea-pig tracheal chains [30]. Similarly,
a recent study indicated that CAR is a novel inhibitor of transient
receptor potential (TRP) channels in drosophila and mammalian
[31]. These studies suggested that CAR may act on membrane
receptors to modulate intracellular signal pathways. So far, no data
showed whether CAR can directly interact with intracellular
proteins or targets by crossing the cellular membrane. However,
more and more evidences demonstrated that intracellular signal
pathways were changed by CAR treatment [32,33,34]. In human
hepatoma HepG2 cells, CAR induces cell apoptosis by selectively
decreasing phosphorylation of extracellular signal-regulated kinase
1/2 (ERK1/2) and P38 [32]; In human macrophage-like U937
cells, in response to lipopolysaccharide treatment, CAR activates
peroxisome proliferator-activated receptors (PPAR alpha and
gamma) and suppresses cyclooxygenase-2 (COX-2) mRNA and
protein expression [33]. The signal pathways of CAR in vivo were
seldom studied. Since our data demonstrated the protective effects,
we further examined the effect of CAR on signal pathways after
cerebral I/R injury. The phosphatidyl inositide3-kinase (PI3K)/
Akt pathway is a critical survival mediator in the signal
transduction pathways after cerebral ischemia and the activation
of PI3K/Akt pathway is a therapeutic target for stroke [35,36]. It
is not clear whether CAR activates PI3K/Akt pathway after
cerebral ischemia injury. In this study, we provided evidences that
the PI3K/Akt activation mediates the protection of CAR in the
cerebral I/R injury model and the inhibition of PI3K/Akt signal
pathway abolishes the protection of CAR (Figures 5 and 6).
Although in our study, PI3K inhibitor LY-294002 almost
completely blocked the protection of CAR, PI3K/Akt signal
pathway may be not the only protective pathway. The antioxidant
activity of CAR may also provide a part of neuroprotection
because previous studies have confirmed the antioxidant proper-
ties of CAR [37,38]. This inconsistence may be explained by the
toxicity of LY-294002 that blocks not only the PI3K/Akt
activation by CAR, but also the activation caused by cerebral
ischemia injury and even the basal level of Akt.
In summary, CAR provides neuroprotection on infarct volume
and neuronal apoptosis in a focal MCAO mouse model. Because
CAR is widely used as a food additive and its safety is well studied
before [39,40], it has a high potential to be translated from bench
research to clinical trials for stroke therapy.
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